Postmenopausal vaginal atrophy (PVA), also known as postmenopausal
atrophic vaginitis, refers to the drying, thinning, and inflammation
of the vaginal walls owing to lower levels of estrogen. Women
suffering from this condition are more susceptible to urinary
function problems and chronic vaginal infections. Today, a number of
treatments and drugs are available that focus on the underlying cause
as well as the symptoms of the condition, helping women improve their
quality of life.
Report Overview @
https://www.transparencymarketresearch.com/postmenopausal-vaginal-atrophy-treatment-Drug.html
The report on the postmenopausal vaginal atrophy treatment and drug
market serves as an ideal tool for those looking to hold a stake in
the global market. The various micro and macro trends influencing
demand and supply have been discussed at length. The study also sheds
light on consumer purchasing patterns and the different factors that
drive the uptake of postmenopausal vaginal atrophy drugs and
treatment options. The vendor landscape also forms a key part of this
publication, with the past and future performance of leading players
thoroughly evaluated by industry experts.
There are a number of factors boosting the postmenopausal vaginal
atrophy treatment and drugs market, the most prominent ones being
favorable healthcare reforms in the U.S. and high unmet medical needs
across emerging economies. The Affordable Care Act (2010), also
referred to as Obamacare after the then-President of the United
States Barack Obama, has greatly encouraged patients with this
condition to seek proper diagnosis and treatment. The availability of
beneficial and comprehensive health insurance reforms in the U.S. has
therefore aided the growth of the postmenopausal vaginal atrophy
treatment and drugs market.
Download Report Brochure @ https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1994
A key trend observed in this market is the gradual shift from
systemic estrogen treatments, such as vaginal gels, creams, and
patches, to non-estrogenic therapies. Nevertheless, between topical
and systemic estrogen drug class, the demand for the former continues
to be high. Rising R&D activities in this field is also a
lucrative trend driving the postmenopausal vaginal atrophy treatment
and drugs market. On the other hand, low diagnosis rates and patent
expiry of branded and blockbuster products threaten to impede market
growth.
The worldwide market for postmenopausal vaginal atrophy treatment and
drugs can be fragmented on the basis of geography into North America,
Asia Pacific, Europe, and Rest of the World. In terms of revenue,
North America is perhaps the most prominent market as of now and is
powered primarily by the U.S. A greater level of awareness about this
condition among women and the willingness as well as ability to
freely discuss its occurrence and symptoms is a major factor driving
the demand for postmenopausal vaginal atrophy treatment and drugs in
the country. Women in the developed countries of North America and
Europe are increasingly aware about the benefits of early diagnosis
and the various treatment options available and this makes these
regions strong markets for postmenopausal vaginal atrophy drugs and
treatments. Favorable reimbursement scenario in these regions is also
a key driving factor.
Pre-Book Full Report @
https://www.transparencymarketresearch.com/checkout.php?rep_id=1994<ype=S
Some of the prominent vendors in the postmenopausal vaginal atrophy
treatment and drugs market are EndoCeutics, Upsher-Smith
Laboratories, TherapeuticsMD, Bionovo, Pfizer, Novo Nordisk,
Allergan, Shionogi, Ligand Pharmaceuticals, Bayer, Pantarhei
Bioscience, Foamix Pharmaceuticals, Pep-Tonic Medical, and Teva
Pharmaceuticals. This highly competitive market is characterized by
the presence of both international and local players and offers
immense scope for growth. Thanks to the development of newer
applications and product and treatment extensions, this competitive
environment is slated to become even more intense in the years to
come.
About Us
Transparency Market Research (TMR) is a market intelligence company,
providing global business information reports and services. Our
exclusive blend of quantitative forecasting and trends analysis
provides forward-looking insight for thousands of decision makers.
TMR’s experienced team of analysts, researchers, and consultants,
use proprietary data sources and various tools and techniques to
gather, and analyze information. Our business offerings represent the
latest and the most reliable information indispensable for businesses
to sustain a competitive edge.
Each TMR syndicated research report covers a different sector - such
as pharmaceuticals, chemicals, energy, food & beverages,
semiconductors, med-devices, consumer goods and technology. These
reports provide in-depth analysis and deep segmentation to possible
micro levels. With wider scope and stratified research methodology,
TMR’s syndicated reports strive to provide clients to serve their
overall research requirement.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email:
sales@transparencymarketresearch.com
Website:
https://www.transparencymarketresearch.com
No comments:
Post a Comment